Product Pipeline
MPL adjuvant, our flagship adjuvant, is a derivative of the lipid A molecule found in gram-negative bacteria, and has been observed to be a potent immunostimulant. GlaxoSmithKline recently completed a Phase III clinical trial of a genital herpes vaccine containing Corixa's MPL adjuvant in which women were shown to have benefited from vaccination.

Related News
10/29/2001 Corixa and Wyeth Lederle Vaccines amend agreement
03/27/2000 Corixa and Wyeth Lederle Vaccines expand alliance
06/10/1999 Corixa to acquire Ribi
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.